Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

PHASE3CompletedINTERVENTIONAL
Enrollment

2,670

Participants

Timeline

Start Date

September 8, 2017

Primary Completion Date

November 2, 2017

Study Completion Date

April 19, 2018

Conditions
Influenza
Interventions
BIOLOGICAL

QIV-HD

0.7 mL-dose was administered intramuscularly (IM) into the upper arm area.

BIOLOGICAL

Licensed TIV-HD1

0.5 mL-dose was administered IM into the upper arm area.

BIOLOGICAL

Investigational TIV-HD2

0.5 mL-dose was administered IM into the upper arm area.

Trial Locations (36)

14609

Sanofi Pasteur Investigational Site 008, Rochester

23507

Sanofi Pasteur Investigational Site 038, Norfolk

27045

Sanofi Pasteur Investigational Site 036, Winston-Salem

28401

Sanofi Pasteur Investigational Site 005, Wilmington

29464

Sanofi Pasteur Investigational Site 033, Mt. Pleasant

30281

Sanofi Pasteur Investigational Site 030, Stockbridge

32205

Sanofi Pasteur Investigational Site 009, Jacksonville

32216

Sanofi Pasteur Investigational Site 017, Jacksonville

33024

Sanofi Pasteur Investigational Site 031, Hollywood

37212

Sanofi Pasteur Investigational Site 001, Nashville

39531

Sanofi Pasteur Investigational Site 026, Biloxi

40004

Sanofi Pasteur Investigational Site 012, Bardstown

44122

Sanofi Pasteur Investigational Site 004, Cleveland

51501

Sanofi Pasteur Investigational Site 021, Council Bluffs

63104

Sanofi Pasteur Investigational Site 014, St Louis

67205

Sanofi Pasteur Investigational Site 023, Wichita

67207

Sanofi Pasteur Investigational Site 028, Wichita

68134

Sanofi Pasteur Investigational Site 011, Omaha

70427

Sanofi Pasteur Investigational Site 018, Metairie

73112

Sanofi Pasteur Investigational Site 015, Oklahoma City

75234

Sanofi Pasteur Investigational Site 002, Dallas

77375

Sanofi Pasteur Investigational Site 025, Tomball

80920

Sanofi Pasteur Investigational Site 016, Colorado Springs

83642

Sanofi Pasteur Investigational Site 034, Meridian

Sanofi Pasteur Investigational Site 022, West Jordan

83712

Sanofi Pasteur Investigational Site 010, Boise

84095

Sanofi Pasteur Investigational Site 020, South Jordan

84109

Sanofi Pasteur Investigational Site 027, Salt Lake City

84121

Sanofi Pasteur Investigational Site 006, Salt Lake City

84123

Sanofi Pasteur Investigational Site 019, Salt Lake City

89104

Sanofi Pasteur Investigational Site 024, Las Vegas

92117

Sanofi Pasteur Investigational Site 003, San Diego

92801

Sanofi Pasteur Investigational Site 037, Anaheim

96001

Sanofi Pasteur Investigational Site 029, Redding

06460

Sanofi Pasteur Investigational Site 035, Milford

02886

Sanofi Pasteur Investigational Site 013, Warwick

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US | Biotech Hunter | Biotech Hunter